Recruiting
Phase 2

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Sponsor:

Rapport Therapeutics Inc.

Code:

NCT06377930

Conditions

Focal Onset Seizures

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

RAP-219

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information